Evotec AG and Padlock Therapeutics, Inc. announced today that they have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases and have further extended the collaboration that was first signed in January 2014. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-padlock-therapeutics-announce-initial-success-and-extension-of-long-term-collaboration-5261
Evotec and Ohio State to collaborate on novel cancer therapy
Evotec AG today announced a research collaboration with the laboratories of Prof. Roger Briesewitz at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ohio-state-to-collaborate-on-novel-cancer-therapy-5259
Achievement of multiple milestones in Evotec's drug discovery alliances
Evotec AG disclosed today that it achieved multiple milestones in ongoing alliances with its strategic research partners. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/achievement-of-multiple-milestones-in-evotecs-drug-discovery-alliances-5257
Evotec and Sanofi enter into exclusive negotiations for a major multi-component strategic collaboration
Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sanofi-enter-into-exclusive-negotiations-for-a-major-multi-component-strategic-collaboration-5251
Evotec reports results of the first nine months of 2014
Evotec AG today reported financial results and corporate updates for the first nine months of 2014. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-results-of-the-first-nine-months-of-2014-5249
Evotec receives milestone as part of its multi-target alliance with Bayer HealthCare
Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-milestone-as-part-of-its-multi-target-alliance-with-bayer-healthcare-5245
Evotec and its partners awarded public grants to develop new drug candidates to treat multiple sclerosis
Evotec AG announced today that it has entered into three novel research projects for the treatment of Multiple Sclerosis supported by research funds from the German Federal Ministry of Education and Research. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and–its-partners-awarded-public-grants-to-develop-new-drug-candidates-to-treat-multiple-sclerosis-5243
Evotec takes legal steps against Andromeda Biotech, Ltd.
Evotec AG announced today after careful evaluation that it will take legal steps against Israel-based Andromeda Biotech, Ltd. to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277®. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-takes-legal-steps-against-andromeda-biotech-ltd-5241
Evotec and the Jain Foundation expand collaboration: Start of multiple drug screening programmes
Evotec AG and the Jain Foundation Inc. today announced that they have further extended and expanded the collaboration first signed in 2012 and extended last year. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-the-jain-foundation-expand-collaboration-start-of-multiple-drug-screening-programmes-5239
Evotec announces update on DiaPep277®
Evotec AG was informed that US company Hyperion Therapeutics, Inc. is terminating the development of DiaPep277® for newly diagnosed Type 1 diabetes. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-update-on-diapep277r-5234